Pulmonology
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Related resources
Learning objectives
- Describe the physiological basis of FeNO production in airways with type 2 inflammation
- Explain how FeNO measurements can aid in the diagnosis of asthma, predict clinical outcomes such as exacerbation risk and lung function, and forecast response to some treatments
Description
Fractional exhaled nitric oxide (FeNO) is a noninvasive biomarker that reflects type 2 airway inflammation. Elevated FeNO levels are a result of increased nitric oxide production by airway epithelial cells. While various factors can influence FeNO levels, its measurement offers valuable insights into asthma management. This infographic explores how FeNO can support the diagnosis of asthma, provide prognostic information regarding lung function decline and exacerbation risk, and predict patient response to some therapies.
Tags
MAT-GLB-2505599 - 1.0 - 09/2027
